• Company
• Forxiga's generics will be suspended until the 7th
• by Kim, Jin-Gu Mar 22, 2023 05:47am

• Company
• 10 years of the global launch of K-biosimilars
• by Chon, Seung-Hyun Mar 22, 2023 05:47am

• Company
• Dupixent likely to expand reimb to pediatrics from April
• by Eo, Yun-Ho Mar 22, 2023 05:46am

• Company
• Patent extension system for drugs to be reorganized…
• by Kim, Jin-Gu Mar 22, 2023 05:46am

• Opinion
• [Reporter's view] PVA improvement plan & domestic drugs
• by Lee, Tak-Sun Mar 21, 2023 05:58am

• Policy
• Janssen's CAR-T treatment Carvykti was approved
• by Lee, Hye-Kyung Mar 21, 2023 05:57am

• Policy
• Which Vemlidy IMD among the 5 will rise to the top?
• by Lee, Tak-Sun Mar 21, 2023 05:57am

• Company
• Pediatric indication becomes key to sales in Korea
• by Moon, sung-ho Mar 21, 2023 05:56am

• Company
• Increasing male infertility
• by Eo, Yun-Ho Mar 21, 2023 05:56am

• Policy
• Erleada applied for health insurance in April
• by Lee, Tak-Sun Mar 20, 2023 05:51am